Anti-Cancer MAbS Market Report 2025

This Anti-Cancer MAbS market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The anti-cancer mabs market size has grown rapidly in recent years. It will grow from $69.33 billion in 2024 to $76.92 billion in 2025 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to increasing cancer incidence rates, growing understanding of cancer biology, rise in personalized medicine approaches, increased investment in research and development, growing patient awareness and demand.

The anti-cancer mabs market size is expected to see strong growth in the next few years. It will grow to $109.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to advancements in immunotherapy, increasing adoption of combination therapies, emergence of next-generation mAbs, global efforts to address cancer burden, expansion of patient access programs. Major trends in the forecast period include innovations in drug delivery technologies, integration of artificial intelligence in drug discovery, collaborations and partnerships in the pharma industry, advancements in biotechnology, car-t cell therapies.

The increasing incidence of cancer worldwide is expected to drive the growth of the anticancer monoclonal antibodies (mAbs) market. Cancer is a chronic disease that affects millions of individuals globally. Anticancer mAbs are designed to target specific proteins found on cancer cells, using genetically engineered versions of the immune system's antibodies to combat cancerous cells. With the rising prevalence of cancer, there is a growing demand for more effective therapies such as anticancer mAbs. For instance, according to a January 2022 report from PubMed, an estimated 1.9 million new cancer cases are anticipated globally, with 609,360 cancer-related deaths expected in the United States. Consequently, the increasing prevalence of cancer is a significant driver for the growth of the anticancer mAbs market.

The increasing number of clinical trials is expected to drive the growth of the anti-cancer monoclonal antibodies (mAbs) market in the future. A clinical trial is a research study that prospectively assigns individuals to one or more health-related interventions to assess the effects of those interventions on health-related biomedical or behavioral outcomes. Clinical trials have been instrumental in the development and refinement of anti-cancer mAbs, providing valuable insights into their safety, efficacy, and potential mechanisms of action. For instance, in May 2023, ClinicalTrials.gov, a platform for registering clinical trials, reported a total of 452,604 clinical trials in 2023, an increase from the 365,000 registered trials in 2021. Therefore, the growing number of clinical trials is contributing to the expansion of the anti-cancer mAbs market.

Product innovation is a prominent trend within the anticancer mAbs market, with major companies introducing more targeted and effective cancer treatments. For example, in May 2022, Roche Holding AG, a Switzerland-based pharmaceutical company, launched PHESGO, a unique combination treatment for HER2-positive early breast cancer. PHESGO consists of two monoclonal antibodies, pertuzumab and trastuzumab, combined with the enzyme hyaluronidase. This subcutaneous injection, leveraging hyaluronidase, enhances mAbs absorption, allowing for subcutaneous administration rather than intravenous, offering patients a more convenient treatment option. Such innovative approaches demonstrate a commitment to developing advanced and patient-friendly therapies within the anticancer mAbs market.

Major players in the anti-cancer monoclonal antibodies (mAbs) market are strategically focusing on innovative strategies, such as conducting clinical trials, to establish a competitive advantage in the industry. Clinical trials are pivotal research studies that assess the safety and efficacy of novel treatments, medications, or devices in human subjects. For instance, in April 2023, Y-mAbs Therapeutics Inc., a prominent clinical biopharmaceutical company based in the United States, initiated a Phase I Trial for GD2-Targeted Radioimmunotherapy. This trial aims to evaluate the safety and effectiveness of GD2-SADA, a pre-targeted radioimmunotherapy (RIT), in treating specific GD2-positive solid tumors such as small cell lung cancer, sarcoma, and malignant melanoma. GD2-SADA follows a distinctive two-step procedure to administer radiation to tumor cells. Initially, the SADA protein attaches to GD2 proteins present on the surface of various solid tumors. Subsequently, the radioactive ligand 177Lu-DOTA is introduced, binding to the SADA protein and delivering radiation specifically to the tumor cells. This two-step approach is devised to limit radiation exposure to healthy tissues.

In June 2024, Merck & Co., Inc., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.8 billion. This acquisition strengthens Merck's portfolio in immunology, especially with Prometheus's lead candidate, PRA023 (now referred to as MK-7240), a monoclonal antibody that targets TL1A, which is associated with autoimmune diseases such as ulcerative colitis and Crohn's disease. Prometheus Biosciences Inc. is a US-based clinical-stage biotechnology company specializing in anti-cancer monoclonal antibodies (mAbs).

Anticancer monoclonal antibodies (mAbs) are antibodies utilized in monoclonal antibody therapy with the aim of targeting and destroying cancer cells. These antibodies are designed to bind to specific proteins or chemicals found on the surface of cancer cells, thereby inhibiting the growth and spread of cancer.

The primary types of anti-cancer mAbs include murine antibodies, chimeric antibodies, humanized antibodies, and others. Murine antibodies are a specific category of monoclonal antibodies that are laboratory-made copies of a single antibody. These antibodies are produced by a single B cell and are derived from mice or rats. They are engineered to bind to a specific antigen. Anticancer mAbs find applications in various cancer types, including blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, among others. These antibodies are used in settings such as hospitals, research institutes, and other medical facilities.

The anti-cancer MABs market research report is one of a series of new reports that provides anti-cancer MABs market statistics, including anti-cancer MABs industry global market size, regional shares, competitors with an anti-cancer MABs market share, detailed anti-cancer MABs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cancer MABs industry. This anti-cancer MABs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the anti-cancer mabs market report are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB .

North America was the largest region in the anti-cancer MAbS market in 2023. Asia Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-cancer mabs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anticancer mAbs market consists of sales of monoclonal antibody therapies such as avastin, Herceptin, keytruda, opdivo, darzalex, and perjeta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.